Arterial hypertension is associated with marked changes in the structure of both resistance and large arteries. The renin-angiotensin system is largely involved in these alterations; chronic blockade of the renin-angiotensin system prevents and/or reverses most of the alterations of the vasculature in experimental and clinical hypertension. In this review we have analysed the differential role of AT 1 and AT 2 receptors in the response of the vessels to arterial hypertension. It emerges that the relative involvement of each receptor
Introduction
The complications of arterial hypertension can be separated into those mainly related to the level of blood pressure (BP) (stroke, aneurysm, left ventricular hypertrophy, congestive failure) and those involving alterations in arterial structure and function (ie, atherosclerosis lesions of cerebral, coronary, renal and peripheral limb arteries) leading to cerebral, myocardial, renal and limb ischaemia and/or infarction. The reduction in arterial BP significantly reduces the incidence of the first group of complications; however, the latter complications, related to alterations of the arterial wall poorly respond to anti-hypertensive therapy. Finally, the disturbing failure of anti-hypertensive drugs to reduce markedly the incidence of myocardial infarction by comparison with the prevention of strokes has focused attention on structural and functional vascular alterations and has prompted research to a better understanding of specific effects of anti-hypertensive agents on the arterial wall. 1, 2 Several arguments have suggested that the antihypertensive agents related to the renin-angiotensin system act, to a large extent, not only on arterioles but also on the large arterial wall. 3 Angiotensin II (Ang II), the main effector peptide of the reninangiotensin system has long been known to play a major role in the regulation of BP and body fluid homeostasis. Moreover, Ang II has been reported to induce hyperplasia and/or hypertrophy in cultured aortic smooth muscle cells [4] [5] [6] [7] in small resistance arteries 8 and in cardiomyocytes. 9 The tissue response to Ang II is mediated by specific receptors located on the cell surface. As defined by their pharmacological receptors, there are two main subtypes of Ang II receptors: AT 1 and AT 2 , specifically blocked by losartan and PD123319, respectively. 10 Both AT 1 and AT 2 receptors contain a seven transmembrane domain but only AT 1 receptor is coupled to G-protein. The AT 1 receptor subtype, predominant in the vascular system, mediates most of the actions of Ang II closely associated with the regulation of vascular tone and extra cellular fluid volume. [11] [12] [13] [14] [15] Much less is known regarding the contribution of AT 2 receptor activation to the biological actions of Ang II. The relative abundance of AT 2 subtype receptors in many fetal tissues supports a role of AT 2 during development. 16, 17 Furthermore, a key role for the AT 2 subtype receptor is suggested by several studies that correlate enhanced AT 2 receptor expression with cardiovascular system disease states such as diabetes, 18 post-myocardial infarction, 19 ischaemia, 20 and hypertension, 21 eg, when cardiovascular remodelling is involved. The ability of a tissue to change the expression of AT 1 to AT 2 receptors has been described in experimentallyinduced vascular injury, 22, 23 suggesting that Ang II may also play a role, through AT 2 receptors, in smooth muscle cell differentiation and proliferation. Furthermore, by transfecting an AT 2 receptor expression vector into the balloon injured rat carotid artery, Nakajima et al 24 reported that overexpression of the AT 2 receptor attenuated neointimal formation.
Finally, haemodynamic data obtained from transgenic mouse lacking Ang II type 2 receptor does not help to fully understand the role of the AT 2 receptor: Ichiki and coworkers reported that the targeted disruption of the mouse AT 2 gene resulted in a significant increase in BP 25 whereas Hein and colleagues reported that mutant mice had normal BP. 26 However, both groups have shown an increased sensitivity to the pressor action of Ang II in mutant mice suggesting a role of the AT 2 receptor in the control of the vasomotricity.
Angiotensin-converting enzyme (ACE) inhibitors and vasculature

Resistance arteries
The first observation on ACE inhibitors and vascular structure goes back to 1980 when Giudicelli et al 27 administered captopril, atenolol, or hydralazine to young (6-week-old) spontaneously hypertensive rats for 14 weeks. These authors reported that captopril almost completely prevented the development of hypertension as did atenolol and hydralazine. The point was that, when treatment was withdrawn, the arterial pressure of the rats that had received atenolol or hydralazine promptly rose to levels measured in age-matched hypertensive rats that had never received therapy, whereas only a small slow rise in pressure was seen in the animals that had been given captopril. This effect was attributed to an antihypertrophic effect of captopril in resistance vessels associated to a significant decrease in media to lumen ratio and therefore to haemodynamic resistance. More recent studies by the same and other groups have been carried out and confirmed these results (See reference 2 for review). However, no strict correlation existed between vascular structure and the rate of rise of pressure when therapy was withdrawn. Extensive review of experimental studies reveals a strikingly small number of studies using genetically hypertensive rats where ACE inhibitors have been given after hypertension was established. Most studies have concentrated upon prevention of hypertension and associated resistance arterial wall structural changes. Therefore it is difficult to establish if, in vivo, ACE inhibitors may alter the structure of resistance vessels independently of BP.
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Large arteries
Whereas blood flow is largely preserved in hypertension, arterial stiffness is significantly increased for the arterial tree as a whole. The arterial stiffening appears largely to be caused by the elevated level of BP as such, but there is increasing evidence that alterations of the arterial wall associated with hypertension also contribute to the changes in the viscoelastic properties of the wall of the large conduit arteries (see review 29). In order to evaluate the role of structural wall alterations on arterial stiffness modification, we have studied the effect of chronic inhibition of ACE on the mechanical function and the histological structure of large arteries in hypertensive rats with renovascular 30 or genetic 31 hypertension. In the hypertensive rats, increased arterial pressure was associated with a stiffer arterial wall, as demonstrated by increased aortic characteristic input impedance, decreased systemic arterial compliance, and decreased isolated carotid compliance. Chronic ACE inhibition after establishment of stable hypertension in 12-week-old rats normalised BP and reversed these in vivo markers of arterial stiffening. These functional changes were obtained in parallel with structural modifications of the thoracic aortic wall even if a cause-to-effect relationship could not be evidenced. The aortic media stiffening observed in hypertensive animals was reversed by treatment and mainly related to a reduction of smooth muscle cell hypertrophy and collagen media content.
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Angiotensin II subtype receptors and arterial structure
Arterial media thickening
Arterial media thickening reflects the adaptation of arterial smooth muscle cells to increased systolic pressure and depends mainly on the systolic pressure level 33, 34 although humoral factors such as Ang II may also be involved. 35 In vitro, Ang II triggers vascular smooth muscle cell (VSMC) hypertrophy, [36] [37] [38] this effect being mediated via the AT 1 receptor. In organotypic culture of segments of rabbit aorta, Bardy et al reported that mechanical factors stimulated local synthesis of Ang II, which in turn induced an increase in the synthesis of extracellular matrix proteins, such as fibronectin and collagen, via the AT 1 receptor. 39, 40 In the same way, van Kleef et al 41 reported that AT 1 but not AT 2 receptors mediate the progression of neointimal thickening induced by delayed application of Ang II in the injured carotid artery in the rat. It should be noted that rabbit aorta expresses the AT 1 subtype receptor only, whereas both AT 1 and AT 2 receptor subtypes are expressed in rat arteries. 42 Therefore, we investigated the effect of chronic pharmacological blockade of AT 1 and AT 2 receptors in the production of vascular wall hypertrophy in rats receiving chronic hypertensive infusion of angiotensin II. Vascular wall hypertrophy was characterised by morphometric analysis combined with either immunohistochemistry or conventional histological staining. Conventional morphometry 43 and image analysis after smooth muscle ␣-actin (SM␣-actin) immunolabelling 44 allowed the evaluation of media thickness in the aorta and coronary arteries respectively. Prolonged Ang II infusion (23 days) induced significant thickening of the media in both aorta and coronary arteries, independent of luminal diameter. Treatment of Ang II-induced hypertensive rats with either losartan or PD123319 resulted in a decrease in media thickness, although PD123319 treatment was more effective. It is noteworthy that the effects of AT 2 blockade were independent of changes in arterial systemic pressure whereas those of AT 1 blockade were indistinguishable from pressor effects. On the other hand, increased medial thickness of aorta and coronary artery was observed in response to chronic AT 1 blockade in normotensive rats, the process being inhibited by concomitant blockade of AT 2 receptors. The finding that treatment of normotensive rats with losartan alone had no effect on BP, but induced medial hypertrophy that was prevented by additional treatment with PD123319, could be related to an already demonstrated increase in plasma Ang II concentration secondary to AT 1 receptor long term blockade. 45 Under our experimental conditions in Ang II-induced hypertension, we suggested that the AT 2 receptors were activated and induced vascular trophic effects. The trophic effect of AT 2 receptor stimulation appeared specific to VSMC and independent of arterial type (ie, conductive or resistive). Whether this is a direct effect or mediated via other cascade(s) has not been investigated. However, recent in vitro data indicate that the AT 2 receptor may be expressed in differentiated smooth muscle cell, its activation triggering an increase in total RNA synthesis. 46 . The in vivo non-invasively measured carotid lumen diameters (echo tracking system) are shown in Figure 1 . The carotid diameter was significantly larger in rats receiving Ang II as compared with the control group (P Ͻ 0.01). Treatment with PD123319 alone or with addition of PD123319 and Ang II resulted in a slight but non-significant decrease in carotid diameter vs values in the control group. However, the carotid diameter was significantly smaller in Ang II + PD123319 group than in the Ang II group (P Ͻ 0.01). In as much as BP was increased in Ang II-infused rats, the increase in the carotid lumen diameter observed in the Ang II group could be related to hypertension, independently on direct effect of Ang II on the vessel growth. However, the addition of AT 2 receptor antagonist to angiotensin II in the Ang + PD123319 group antagonised both increases in carotid lumen diameter and in aortic wall thickness, but did not affect the increase in arterial pressure. Taken together, these results suggest that the carotid lumen enlargement and the Figure 1 In vivo values of the carotid lumen diameter of normotensive rats (control), angiotensin-induced hypertensive rats (Ang II), rats receiving infusion of Ang II plus AT 2 blocker (Ang II + PD 123319) or AT 2 blocker alone (PD 123319). Adapted from Levy et al. 43 aortic hypertrophy in the Ang II group resulted from growth processes mediated through AT 2 subtype receptor.
Therefore results obtained in vivo and in vitro support the hypothesis that the AT 2 receptor activation plays a major role in the development of vascular hypertrophy in the rat, when vascular smooth muscle cells are not in an active proliferative stage. Furthermore, AT 2 receptor blockade in normotensive rats is associated with a shift of VSMC towards an immature phenotype, suggesting the unmasking of an AT 1 receptor transactive pathway which mediates phenotypic changes. 44 Therefore, the qualitative and quantitative changes in aortic and coronary arterial phenotype secondary to Ang IIinduced hypertension appear to be triggered by two independent pathways: (1) Ang II induces medial hypertrophy of both aorta and coronary arteries, via the AT 2 receptor, independent of changes in BP; and (2) phenotypic changes in VSMC are controlled through AT 1 receptor activation and/or BP elevation. These data contrast with previous studies which demonstrated AT 1 -triggered cell growth and/or hypertrophy whereas AT 2 mediated inhibition of cell replication. It is noteworthy that most of the anti-proliferative function of the AT 2 receptor has been observed in non-muscle cells (endothelial cells or R3T3 fibroblasts in culture) or in smooth muscle cells actively replicating after endothelial injury.
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Angiogenesis
Ang II is an angiogenic molecule in various angiogenesis assays. Le Noble and colleagues 47 reported that Ang II may not act by influencing endothelial cell proliferation and migration like most other angiogenic factors but that its primary target is the vascular smooth muscle. Ang II may act as a mitogen for vascular smooth muscle and enhance their anchoring in the vessel wall. The mechanism of the latter effect remains unknown but could involve the activation of extracellular matrix components or cell-cell adhesion forces within the vessel wall. The outcome of this action is enhanced arterialisation. ACE inhibitors attenuate angiogenesis in different mammalian 48, 49 and avian 50 models. Evidence of a non-AT 1 , non-AT 2 receptor angiotensin II receptor has been obtained in human endometrial material. 51 The expression of this new subtype receptor is highest in the proliferative, angiogenic phase of the menstrual cycle. Le Noble et al 50 also proposed the existence of such a non-AT 1 , non-AT 2 receptor in the chick embryo chorio-allantois membrane. Thus we may be dealing with a receptor that is normally suppressed, but activated by stimuli that induce angiogenesis. Studies to establish the molecular nature and signal transduction mechanism of this receptor are now in progress.
Conclusions and perspectives
In this review we have analysed the differential role of AT 1 and AT 2 receptors in the response of the vessels to arterial hypertension. It emerges that the rela-tive involvement of each receptor depends on cell type, the studied specie, and experimental condition. Several points must be investigated in the near future, and especially: (1) the precise role of angiotensin receptors in different cell types and different stages of differentiation; (2) the transduction pathway used by the AT 2 receptor in different cell types; (3) the possible interactions between the two receptor subtypes; and finally, (4) a possible role of (a) new subtype(s) of Ang II receptor.
